

M. VAUGHN EMERSON, M.D.

Wilmer Eye Institute
600 North Wolfe Street, Wilmer B-20
Baltimore, MD 21287

410-955-5700 (w)
410-215-6496 (c)
memerso4@jhmi.edu

Education/Training

A.B., *magna cum laude*, Biochemical Sciences, Harvard University, Cambridge, MA, (1997).

M.D., Yale University School of Medicine, New Haven, CT, (2001).

Internship, Department of Internal Medicine, University of Hawaii, Honolulu, HI (2001-2002).

Residency, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD (2002-2005).

Fellowship, Retina Division, Casey Eye Institute, Oregon Health & Science University, Portland, OR (2005-2007).

Academic Appointment

Assistant Chief of Service, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD (2007-2008).

Certification

American Board of Ophthalmology Diplomate, 10/29/2006

Licensure

Oregon MD25674, 4/15/2005
Maryland D0065544, 1/29/2007

Professional Organization Memberships

American Academy of Ophthalmology (2002-present)
Association of Research in Vision and Ophthalmology (1998-present)
Wilmer Resident's Association (2002-present)

Peer-reviewed Journal Reviewer

Journal of Glaucoma (2006-present)
Ophthalmology (2005-present)

Academic Awards

Ronald G. Michels Fellowship Foundation Award (2006)
Arnall J. Patz Research Grant Award (2004)
Lee E. Farr honorary scholarship for original research in the medical sciences (1999)

Selected Publications

Original Articles

1. Emerson GG, Flaxel CJ, Lauer AK, Stout JT, **Emerson MV**, Nolte SK, Wilson DJ, Klein ML. Optical coherence tomography findings during pegaptanib therapy for neovascular age-related macular degeneration. *Retina* 2007;27:724-9.
2. **Emerson MV**, Green WR. Ocular autopsy and histopathologic features of child abuse. *Ophthalmology* 2007;114:1384-94.
3. **Emerson MV**, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. *Retina* 2007;27:439-44.
4. **Emerson MV**, Pieramici DJ, Stoessel KM, Berreen JP, Gariano RF. Incidence and rate of disappearance of neonatal retinal hemorrhages. *Ophthalmology* 2001;108:36-39.
5. Sullivan KM, Kansu E, Storer B, Jocom J, Emerson G, Reagan T, **Emerson MV**, Siadak MF, Davis C, Appelbaum FR, Buchkner CD, Hansen JA, Shulman HM, Storb R, McDonald GB. Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation. *Biology of Blood and Marrow Transplantation* 1998;4:20-26.

Book Chapters

1. **Emerson MV**. Subretinal Neovascular Membranes. In Roy FH, Fraunfelder FW, eds. *Current Ocular Therapy*, 6th ed. London: Elsevier, 2006.
2. **Emerson MV**, and Stout JT. Acquired Retinoschisis. In Roy FH, Fraunfelder FW, eds. *Current Ocular Therapy*, 6th ed. London: Elsevier, 2006.
3. Suh L, **Emerson MV**, Jun AS. Fuchs Endothelial Dystrophy. In Reinhard T, Larkin F, eds. *Essentials in Ophthalmology: Cornea and External Disease*, 1st ed. New York: Springer, 2006.
4. **Emerson MV**, and Yap R. Section III: Review Resources. In Bhushan V, Le T, Amin C. *First Aid for the USMLE Step 1*. Stamford, CT: Appleton & Lange, 1999.

Invited Articles

1. **Emerson MV**, Lauer AK. Emerging therapies for the treatment of age-related macular degeneration. *Clinical Ophthalmol* In press.
2. **Emerson MV**, Lauer AK. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. *BioDrugs* 2007;21:254-57.
3. **Emerson MV**, Flaxel CJ (case report discussants). Diagnostic and Therapeutic Challenge. *Retina* 2007;27:253-8.

Invited Presentations

1. Emerging therapies for the treatment of neovascular age-related macular degeneration. Oregon Ophthalmological Alumni Association annual meeting, May, 2007.

Abstracts

1. **Emerson MV**, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Presented at Club Jules Gonin/Retina Society annual meeting, October, 2006.
2. **Emerson MV**, McFarland TJ, Appukuttan B, Zhang Y, Westfall AC, Stout JT. Effect of the soluble VEGF receptors sKDR and sNRP-1 on retinal vascular integrity in a rabbit model of vascular

permeability. Presented at Association of Research in Vision and Ophthalmology annual meeting, May, 2006.

3. **Emerson MV**, Bressler S, Brown JC, Bressler N. The optical coherence tomography features of idiopathic parafoveal telangiectasis. Presented at Wilmer Residents Association Clinical Meeting, April, 2005.
4. **Emerson MV**, Green WR. Ocular autopsy and histopathologic features of child abuse. Presented at American Association of Eye Pathologists annual meeting, October, 2004.
5. **Emerson MV**, Lai JC. Bilateral central retinal vein occlusion. Presented at Wilmer Residents Association Clinical Meeting, May, 2003.
6. **Emerson MV**, DeBroff BD, Shafranov GS. Effect of cataract surgery on retinal nerve fiber layer parameters measured by scanning laser polarimetry. Presented at Association of Research in Vision and Ophthalmology annual meeting, May, 2001.
7. **Emerson MV**, Pieramici DJ, Stoessel KM, Berreen JP, Gariano RF. Incidence and rate of disappearance of neonatal retinal hemorrhages. Presented at Association of Research in Vision and Ophthalmology annual meeting, May, 1999.